Cargando…

Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention

Percutaneous coronary intervention (PCI) with stent placement is a standard treatment for coronary artery disease (CAD). In-stent restenosis after PCI remains a challenging clinical problem. In China, Chinese herbal medicines (CHMs) are widely used for preventing restenosis. This paper systematicall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Guo-Hua, Liu, Jian-Ping, Wang, Nissi S., Chen, Hai-Ying, Chu, Jian-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292238/ https://www.ncbi.nlm.nih.gov/pubmed/22454659 http://dx.doi.org/10.1155/2012/253409

Ejemplares similares

In stent restenosis after percutaneous coronary intervention
por: Eyüboğlu, Mehmet
Publicado: (2016)

The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention
por: Tang, Long, et al.
Publicado: (2019)

Impact of anemia on in-stent restenosis after percutaneous coronary intervention
por: Hu, Huilin, et al.
Publicado: (2021)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention
por: Zhang, Gai, et al.
Publicado: (2020)

New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent
por: Wang, Jian-Long, et al.
Publicado: (2018)

Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention
por: Hou, Ling, et al.
Publicado: (2023)

Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis
por: Joo, Hyung Joon, et al.
Publicado: (2018)

Risk factors associated with intra-stent restenosis after percutaneous coronary intervention
por: Alexandrescu, Dan-Mihai, et al.
Publicado: (2021)

In-stent restenosis after percutaneous coronary intervention: emerging knowledge on biological pathways
por: Pelliccia, Francesco, et al.
Publicado: (2023)

Arterial stiffness in patients with coronary artery disease: relation with in-stent restenosis following percutaneous coronary intervention
por: Prskalo, Zrinko, et al.
Publicado: (2016)

Relationship between ALDH2 genotype and in-stent restenosis in Chinese Han patients after percutaneous coronary intervention
por: Lv, Lizhi, et al.
Publicado: (2019)

Calculating the overall risk of within-stent restenosis after multilesion percutaneous coronary intervention
por: Parviz, Yasir, et al.
Publicado: (2013)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention: Retraction
Publicado: (2020)

Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention
por: Zheng, Jian-Feng, et al.
Publicado: (2020)

Coated stents to prevent restenosis in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2005)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Factors Affecting In-stent Restenosis in Patients Undergoing Percutaneous Coronary Angioplasty
por: Sajadian, Mostafa, et al.
Publicado: (2018)

Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents
por: Zhu, Yong, et al.
Publicado: (2021)

Serum glycated albumin is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents: An observational study
por: Lin, Xiao Long, et al.
Publicado: (2022)

Hypersensitivity and in-stent restenosis in coronary stent materials
por: Hu, Wansong, et al.
Publicado: (2022)

Albumin to globulin ratio was associated with in‐stent restenosis and revascularization events after percutaneous coronary intervention
por: Zhang, Rui, et al.
Publicado: (2022)

Platelet Distribution Width on Admission Predicts In-Stent Restenosis in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Treated with Percutaneous Coronary Intervention
por: Hu, Cheng-Ping, et al.
Publicado: (2018)

Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management
por: Abouelnour, Amr, et al.
Publicado: (2022)

Predictors of restenosis following percutaneous coronary stent implantation: The role of trimetazidine therapy
por: Csató, Gábor, et al.
Publicado: (2022)

Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention
por: Guo, Xuantong, et al.
Publicado: (2023)

SOCS1 gene promoter methylation status is associated with in-stent restenosis after percutaneous coronary intervention
por: Zhou, Liang, et al.
Publicado: (2017)

The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do
por: Wang, Pengfei, et al.
Publicado: (2020)

Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention
por: He, Wenbo, et al.
Publicado: (2021)

Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China
por: Li, Mingrui, et al.
Publicado: (2022)

Outcomes of Percutaneous Coronary Intervention for In‐Stent Restenosis Versus De Novo Lesions: A Meta‐Analysis
por: Elbadawi, Ayman, et al.
Publicado: (2023)

Vascular Endothelial Growth Factor Genetic Variant Is Associated with in-Stent Restenosis after Percutaneous Coronary Intervention
por: Asgarbeik, Saeedeh, et al.
Publicado: (2022)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Visit-to-visit HbA(1c) variability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention
por: Yang, Chen Die, et al.
Publicado: (2020)

Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis
por: Zhao, Shi-jie, et al.
Publicado: (2016)

Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up
por: Cheng, Gong, et al.
Publicado: (2019)

Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis
por: Meier, Pascal, et al.
Publicado: (2012)

The effectiveness of Salvianolate injection for in-stent restenosis after percutaneous coronary intervention: A protocol for systematic review and meta-analysis
por: Zhang, Miao, et al.
Publicado: (2022)

Mean Corpuscular Volume Predicts In-Stent Restenosis Risk for Stable Coronary Artery Disease Patients Receiving Elective Percutaneous Coronary Intervention
por: Sun, Lin, et al.
Publicado: (2019)

Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study
por: Zhang, Ling, et al.
Publicado: (2021)

Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting for Treating In-Stent Restenosis in Unprotected-Left Main: LM-DRAGON-Registry
por: Wańha, Wojciech, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bk24a0fuuqes5jl4ha4j61vn57